Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)

Next Previous
X
Search
Trial Profile

A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Lodapolimab (Primary) ; LY 3321367 (Primary) ; Merestinib (Primary) ; Ramucirumab (Primary)
  • Indications Adenocarcinoma; Adrenal cancer; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Intestinal cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms PACT
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 26 Sep 2024 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2024 Planned End Date changed from 29 Mar 2024 to 1 Jul 2024.
    • 05 Dec 2023 Planned End Date changed from 6 Dec 2023 to 29 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top